The acetylcholinesterase inhibitor donepezil (Aricept) failed to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors, a placebo-controlled trial showed. After 24 weeks ...
The US Food and Drug Administration (FDA) has approved donepezil transdermal system (Adlarity) for patients with mild, moderate, or severe Alzheimer's disease (AD), the manufacturer has announced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results